Show simple item record

dc.contributor.authorTimofte, Irina
dc.contributor.authorWijesinha, Marniker
dc.contributor.authorVesselinov, Roumen
dc.contributor.authorKim, June
dc.contributor.authorReed, Robert
dc.contributor.authorSanchez, Pablo G
dc.contributor.authorLadikos, Nicholas
dc.contributor.authorPham, Si
dc.contributor.authorKon, Zachary
dc.contributor.authorRajagopal, Keshava
dc.contributor.authorScharf, Steven M
dc.contributor.authorWise, Robert
dc.contributor.authorSternberg, Alice L
dc.contributor.authorKaczorowski, David
dc.contributor.authorGriffith, Bartley
dc.contributor.authorTerrin, Michael
dc.contributor.authorIacono, Aldo
dc.date.accessioned2021-09-13T18:20:49Z
dc.date.available2021-09-13T18:20:49Z
dc.date.issued2020-04-01
dc.identifier.urihttp://hdl.handle.net/10713/16616
dc.description.abstractBackground: COPD patients account for a large proportion of lung transplants; lung transplantation survival benefit for COPD patients is not well established. Methods: We identified 4521 COPD patients in the United Network for Organ Sharing (UNOS) dataset transplanted from May 2005 to August 2016, and 604 patients assigned to receive pulmonary rehabilitation and medical management in the National Emphysema Treatment Trial (NETT). After trimming the populations for NETT eligibility criteria and data completeness, 1337 UNOS and 596 NETT patients remained. Kaplan–Meier estimates of transplant-free survival from transplantation for UNOS, and NETT randomisation, were compared between propensity score-matched UNOS (n=401) and NETT (n=262) patients. Results: In propensity-matched analyses, transplanted patients had better survival compared to medically managed patients in NETT (p=0.003). Stratifying on 6 min walk distance (6 MWD) and FEV1, UNOS patients with 6 MWD <1000 ft (∼300 m) or FEV1 <20% of predicted had better survival than NETT counterparts (median survival 5.0 years UNOS versus 3.4 years NETT; log-rank p<0.0001), while UNOS patients with 6 MWD ≥1000 ft (∼300 m) and FEV1 ≥20% had similar survival to NETT counterparts (median survival, 5.4 years UNOS versus 4.9 years NETT; log-rank p=0.73), interaction p=0.01. Conclusions: Overall survival is better for matched lung transplant patients compared with medical management alone. Patients who derive maximum benefit are those with 6 MWD <1000 ft (∼300 m) or FEV1 <20% of predicted, compared with pulmonary rehabilitation and medical management.en_US
dc.description.urihttps://doi.org/10.1183/23120541.00177-2019en_US
dc.language.isoenen_US
dc.publisherEuropean Respiratory Societyen_US
dc.relation.ispartofERJ Open Researchen_US
dc.rightsCopyright ©ERS 2020.en_US
dc.subjectpulmonary rehabilitationen_US
dc.subject.meshLung Transplantationen_US
dc.subject.meshPulmonary Disease, Chronic Obstructiveen_US
dc.subject.meshSurvival Analysisen_US
dc.titleSurvival benefit of lung transplantation compared with medical management and pulmonary rehabilitation for patients with end-stage COPDen_US
dc.typeArticleen_US
dc.identifier.doi10.1183/23120541.00177-2019
dc.identifier.pmid32363207
dc.source.volume6
dc.source.issue2
dc.source.countryUnited States
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record